Aim This research aims to develop potential therapeutic nanostructures (NSs) encapsulating
metformin (MET) and erlotinib (ER) for combinational therapy in breast cancer. Methods …

… We compared gut absorption of inhibitors of epidermal growth factor receptor (erlotinib,
gefitinib, and afatinib), ALK-cMET (crizotinib), PDGFR/BCR-Abl (dasatinib), and multikinase …

… Patients were randomised to receive chemotherapy(Gemcitabine/docetaxel/paclitaxel/vinorelbine)
or TKI (erlotinib or gefitinib). Patients were evaluated at every visit for clinical benefit …

… comparative study … study revealed that LKB1 loss increases AREG, triggering aberrant
EGFR signaling critical for lung cancer growth, and AREG expression might impact the Erlotinib …

… To take a look at whether or not induction of cell cycle arrest contributed to the antiproliferative
efficiency of erlotinib and resveratrol in non-small lung cancer cells, we carried out cell …

… However opposed to our study, the maintenance therapy consisted only of erlotinib
monotherapy and not of a combination with docetaxel and patients were not selected on EGFR-WT …

… erlotinib has been associated with a variety of adverse … eruptive nevi while on erlotinib for
metastatic lung cancer. … one prior report of eruptive nevi related to erlotinib [7], which was part …

… )-doped montmorillonite/poly(N-isopropylacrylamide-co-N,N′-methylene-bis-acrylamide)
[CN/MT/P(NIPA-co-MBA)] smart nanocomposites (NCs) were developed for efficient erlotinib …

… After excluding ineligible patients, the remaining 5975 patients constituted our study cohort,
including 4340 in the gefitinib cohort and 1635 in the erlotinib cohort. The TKI cohorts were …

… To see the binding mode of deferent classes of erlotinib carefully … study, we successfully
docked EFGR protein with erlotinib derivatives to give new insight for drug interaction study…